STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH)
The STOPAH trial closed to patient recruitment in 2015.
The original ‘STOPAH’ Trial (STeroids Or Pentoxyifylline for Alcoholic Hepatitis) was a large clinical trial researching the best treatment option for patients with acute alcoholic hepatitis – liver disease caused by excessive alcohol consumption. The trial was conducted from 2011-2015. The trial finished and the results were published in an academic journal in 2015.
New research using data from the STOPAH trial
The research team want to undertake further analysis of the STOPAH trial data to learn more about the participants. The research team also want to link the participant trial data to further healthcare data to help us better understand this disease.
Patients with liver disease due to alcohol are known to die early. If patients are able to stop drinking alcohol after hospital admission, their chance of survival improves. If they cannot stop drinking alcohol, they are more likely to be readmitted to hospital in the future. Outcomes for the patient are poor and NHS resource use is high.
The team want to identify and understand the health and social factors that are associated with recidivism and mortality for patients with alcoholic hepatitis. The team also want to accurately quantify the healthcare resources associated with this condition in the 5 years before and in the 5-10-year period after hospital admission. Data linked to patients recruited to the STOPAH trial are an extremely valuable resource with which to answer these questions and can be obtained via NHS Digital.
The new knowledge and understanding is likely to inform UK health policy to improve the care for patients suffering from this and related conditions in future.
Mechanism to opt-out of data sharing
All information that was collected about patients in the study has been kept strictly confidential. If you do not want to continue in the study you can withdraw from the study at any time without giving reason. You can contact us at email@example.com and this will be actioned.